BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12142788)

  • 21. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005.
    Brennan B; De Salvo GL; Orbach D; De Paoli A; Kelsey A; Mudry P; Francotte N; Van Noesel M; Bisogno G; Casanova M; Ferrari A
    Eur J Cancer; 2016 Jun; 60():69-82. PubMed ID: 27082136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience.
    Fidani P; De Ioris MA; Serra A; De Sio L; Ilari I; Cozza R; Boldrini R; Milano GM; Garrè ML; Donfrancesco A
    J Neurooncol; 2009 Apr; 92(2):177-83. PubMed ID: 19048188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney.
    Kato M; Koh K; Oshima K; Oguma E; Uchida H; Kishimoto H; Kikuchi A; Hanada R
    Pediatr Int; 2013 Apr; 55(2):245-8. PubMed ID: 23679167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies.
    Athale UH; Duckworth J; Odame I; Barr R
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):651-63. PubMed ID: 19707161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin.
    Furtwängler R; Nourkami-Tutdibi N; Leuschner I; Vokuhl C; Niggli F; Kager L; Ebinger M; Frühwald MC; Graf N;
    Cancer Genet; 2014 Sep; 207(9):434-6. PubMed ID: 25242089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Malignant teratoid/rhabdoid tumour: long-term survival.
    Fisher BJ; Dennis KE; Ang LC
    Can J Neurol Sci; 2007 May; 34(2):245-7. PubMed ID: 17598607
    [No Abstract]   [Full Text] [Related]  

  • 27. Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
    Wong CI; Benedetti DJ; Kao PC; Ma C; Marcus KJ; Mullen EA
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30422. PubMed ID: 37218455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
    Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cure in a case of primary hepatic lymphoma.
    Murthy SA; Singh B; Bhalla S; Arora A; Vohra R; Aggarwal S
    Indian J Cancer; 2000 Dec; 37(4):165-72. PubMed ID: 12018569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK).
    Melchior P; Dzierma Y; Rübe C; Graf N; Kager L; Dieckmann K; Kroiss S; Hubertus J; Warmann S; Schenk JP; Leuschner I; Nemes K; Meier CM; Vokuhl C; Frühwald M; Furtwängler R
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):667-675. PubMed ID: 32407933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful Treatment of Extra-Renal Noncerebral Rhabdoid Tumors with VIDE.
    Yasui N; Yoshida A; Kobayashi E; Nakatani F; Kawamoto H
    Pediatr Blood Cancer; 2016 Feb; 63(2):352-4. PubMed ID: 26469354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and pathologic characteristics of pediatric rhabdoid tumor of kidney].
    Wu Y; Yang WP; Xiao Q; Chen Y; Zeng ST; Xu HY; Huang H; Zou Y; Zhong HS
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):336-7. PubMed ID: 21756830
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination chemotherapy using vincristine, adriamycin, cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) for advanced soft tissue sarcomas: a phase II study.
    Palumbo R; Palmeri S; Gatti C; Villani G; Cesca A; Toma S
    Oncol Rep; 1998; 5(1):69-72. PubMed ID: 9458296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful management of rhabdoid tumor of the liver.
    Jayaram A; Finegold MJ; Parham DM; Jasty R
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):406-8. PubMed ID: 17551403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant rhabdoid tumour of the uterine cervix.
    Tsuda H; Maed K; Hashiguchi Y; Inoue T; Kobayashi Y; Umesaki N; Yamamoto K
    BJOG; 2001 Jan; 108(1):120-3. PubMed ID: 11212987
    [No Abstract]   [Full Text] [Related]  

  • 38. Malignant rhabdoid tumor presenting as a hemangioma.
    Albregts AE; Hebert AA; Aboul-Nasr RA; Raney RB
    Pediatr Dermatol; 1996; 13(6):468-71. PubMed ID: 8987055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.